About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
stock information
press releases
events and webcasts
corporate presentations
Financial Statements
SEC filings
Regulated information
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
All
2019
2018
2017
2016
2015
2014
02
Dec 2019
16:30 E.S.T.
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Read more
20
Nov 2019
16:30 E.S.T.
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
Read more
13
Nov 2019
16:30 E.S.T.
Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications
Read more
06
Nov 2019
16:47 E.S.T.
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Read more
31
Oct 2019
16:30 E.S.T.
Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST
Read more
30
Oct 2019
16:30 E.S.T.
The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement
Read more
1
2
3
Next